

Recent Trends in Solubility Enhancement Techniques for Poorly Water-Soluble Drugs

Mukta Jagtap*

Department of Pharmaceutics, D. K. Patil Institute of Pharmacy, Loha Nanded India 431708

ABSTRACT

The solubility of an active pharmaceutical ingredient (API) plays a pivotal role in determining its bioavailability after oral administration. Poor aqueous solubility, common among many new drug candidates, can lead to inconsistent absorption, necessitating higher doses and complex formulations, which in turn increase development costs. The Biopharmaceutical Classification System (BCS) highlights this challenge, especially for Class II and Class IV drugs, which exhibit low solubility. To address these issues, recent advancements have focused on enhancing solubility through innovative formulation techniques. Amorphous Solid Dispersions (ASDs), produced via Hot-Melt Extrusion (HME) and Spray Drying, improve dissolution by maintaining drugs in a high-energy amorphous state. Nanosuspensions increase surface area and dissolution rate by reducing particle size. Lipid-Based Drug Delivery Systems (LBDDS), including Self-Microemulsifying Drug Delivery Systems (SMEDDS), enhance solubility through lipid solubilization mechanisms. Other emerging strategies include co-crystals, which modify the drug's crystalline structure to improve solubility, and mesoporous silica materials that offer high surface area and controlled release properties. These technologies are gaining traction in the pharmaceutical industry due to their effectiveness and scalability. This review aims to critically evaluate these modern approaches, focusing on their mechanisms, manufacturing feasibility, and current adoption trends over the past decade.

Keywords: Solubility Enhancement, Poorly Water-Soluble Drugs, Bioavailability, Amorphous Solid Dispersions (ASDs), Nanosuspensions, Lipid-Based Drug Delivery Systems (LBDDS), Biopharmaceutical Classification System (BCS)

INTRODUCTION

The solubility of a drug in aqueous media is a critical physicochemical property that fundamentally dictates its therapeutic efficacy. For an orally administered drug to exert its systemic effect, it must first dissolve in the gastrointestinal fluids to be absorbed across the biological membranes and reach the systemic circulation. This process, known as drug bioavailability, is often rate-limited by dissolution for compounds with poor aqueous solubility.

Importance of Solubility in the Biopharmaceutical Classification System (BCS)

The Biopharmaceutical Classification System (BCS) classifies drugs into four categories based on their aqueous solubility and intestinal permeability^[1]. BCS Class II drugs exhibit low solubility but high permeability; their absorption is typically dissolution rate-limited^[6]. BCS Class IV drugs suffer from both

low solubility and low permeability, posing the most significant challenge in formulation development^[7]. For BCS Class II drugs, improving the dissolution rate (i.e., solubility) is a primary focus for enhancing bioavailability. The BCS framework is widely used in pharmaceutical development and regulation to waive *in vivo* bioequivalence studies^[1].

Challenges Posed by Low Solubility on Drug Development and Patient Compliance

Low aqueous solubility presents numerous hurdles throughout the drug development lifecycle: limited and variable absorption, resulting in unacceptably low or highly variable systemic drug concentrations^[3]. This often necessitates higher doses to achieve the desired therapeutic concentration, potentially increasing production costs and the risk of dose-related side effects^[4]. Furthermore, developing conventional dosage forms for poorly soluble drugs is challenging, leading to complex and expensive

Relevant conflicts of interest/financial disclosures: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.



formulation strategies [4, 5]. It is estimated that up to 70% of new chemical entities (NCEs) being discovered possess poor water solubility, underscoring the magnitude of this problem in modern pharmaceutical research [3, 5].

Recent Trends and Innovations in Solubility Enhancement Techniques

The field of solubility enhancement is rapidly evolving, moving toward sophisticated, often nanotechnology-based, and solid-state manipulation methods.

- **Amorphous Solid Dispersions (ASDs):** The drug is molecularly dispersed in an amorphous (non-crystalline) state within a polymer matrix via Hot-Melt Extrusion (HME) or Spray Drying (SD) [4]. Amorphous forms have higher free energy, resulting in enhanced apparent solubility and faster dissolution [13].
- **Co-crystallization:** This involves the formation of a crystalline material composed of the API and a

neutral co-former molecule held together by non-covalent interactions (hydrogen bonds), altering the crystal lattice energy for improved dissolution [2, 15].

- **Nanosuspensions:** These are ultrafine pure drug particles (10-1000 nm) dispersed in a liquid medium. The size reduction increases the surface area and, due to the Ostwald-Freundlich equation, the saturation solubility [3, 10].
- **Lipid-Based Drug Delivery Systems (LBDDS):** Formulations like SMEDDS/SNEDDS use oils, surfactants, and co-solvents to present the drug in a pre-dissolved, readily absorbable form, bypassing the dissolution step for BCS Class II drugs [4, 20].
- **Mesoporous Silica Materials (MSMs):** These are high surface area carriers (e.g., MCM-41) that stabilize the drug in an amorphous state within their pores, preventing recrystallization by providing steric hindrance [12].




Figure 1: Solubility Enhancement Techniques [8]

Classification of Poorly Water-Soluble Drugs

BCS Class II and IV Drugs: Characteristics and Challenges

BCS Class II drugs are characterized by low solubility but high permeability. Their absorption is typically dissolution rate-limited, making the enhancement of solubility and dissolution rate the primary formulation goal [6]. In contrast, Class IV drugs have both low

solubility and low permeability, representing the most challenging class as they require simultaneous strategies to address both low dissolution and poor membrane transport [7].

Impact of Poor Solubility on Drug Dissolution and Absorption

Poor solubility directly impedes drug absorption by several mechanisms. First, the Noyes-Whitney equation dictates that the dissolution rate is

proportional to the drug's saturation solubility results in a slow dissolution, meaning the drug may pass through the gastrointestinal tract before adequate dissolution^[8]. Second, this incomplete dissolution leads to incomplete absorption, resulting in low and variable systemic drug concentrations and reduced bioavailability^[4]. Third, poorly soluble drugs are highly susceptible to variations in pH and food effects, leading to significant inter-patient variability in drug response^[9].

MATERIALS AND METHODS

• Conventional Solubility Enhancement Techniques

Particle Size Reduction

The goal is to increase the effective surface area exposed to the dissolution medium, thus increasing the dissolution rate^[8]. Micronization reduces particle size to the micrometer range (approx 1 - 10 μm) via jet milling, a standard and cost-effective method^[10]. Nanonization (Nanocrystallization) further reduces particle size to the nanometer range (approx. 10 – 1000 nm), significantly increasing the surface area^[11]. Methods include Wet Bead Milling (Top-Down), which uses high-shear stress to break down coarse drug particles, and High-Pressure Homogenization (HPH), which forces the suspension through a narrow gap under high pressure^[11, 12].

Solid Dispersions

A Solid Dispersion (SD) involves dispersing the drug in an inert carrier matrix^[13]. The drug is often converted to its high-energy amorphous state. Polymeric carriers (e.g., HPMC-AS) are essential for inhibiting drug molecule mobility, which prevents the drug's recrystallization (often called the "parachute" effect) during storage and *in vivo* exposure^[13].

Salt Formation and Co-crystallization

These are chemical or crystal engineering modifications. Salt Formation involves reacting an ionizable drug (acid/base) with a counter-ion. Salt forms have dramatically higher dissolution rates because they change the pH of the diffusion layer surrounding the particle, favoring dissolution^[14]. Co-crystallization is the creation of a multi-component

crystal of an API and a neutral co-former linked by non-covalent bonds. This alters the crystal lattice energy, improving dissolution properties, particularly for non-ionizable drugs^[15].

Cosolvency and Hydrotropy

These are liquid-state techniques using auxiliary agents. Cosolvency utilizes water-miscible organic solvents (e.g., ethanol, PEG) to reduce the polarity of the aqueous solution, increasing the drug's solubility^[16]. Hydrotropy uses high concentrations (10% w/v) of hydrotropes (e.g., sodium benzoate) to form soluble aggregates with the drug, increasing apparent solubility without micelle formation^[17].

• Emerging and Advanced Techniques

Nanotechnology-Based Approaches

Nanocrystals are pure drug nanoparticles that offer greatly enhanced dissolution due to increased surface area and higher saturation solubility based on the Ostwald-Freundlich relationship^[10]. Polymeric Micelles are self-assembled structures where amphiphilic block copolymers encapsulate the hydrophobic drug in a non-polar core. Similarly, Dendrimers are highly branched polymers with internal cavities that solubilize the drug, resulting in high solubility enhancement and potential for targeted delivery^[18, 19].

Self-Emulsifying Drug Delivery Systems (SEDDS)

SEDDS are isotropic mixtures of oil, surfactant, and co-solvent that spontaneously form fine oil-in-water emulsions (e.g., microemulsions, nanoemulsions) upon contact with fluid^[20]. This presents the drug in a pre-dissolved state, entirely bypassing the dissolution step for BCS Class II drugs. This is utilized in oral delivery for highly lipophilic drugs, often leveraging lymphatic transport to avoid hepatic first-pass metabolism, enhancing bioavailability and reducing variability^[21].

Supercritical Fluid Technology

Supercritical Fluid Technology is used to manipulate particle formation. Processes like Rapid Expansion of Supercritical Solutions (RESS) and Supercritical Anti-Solvent (SAS) precipitate the drug, yielding

highly pure, ultra-fine nanoparticles with a narrow size distribution, leading to enhanced dissolution [22, 23]. A major advantage is the easy removal of the CO₂, resulting in a solvent-free product [23].

Liquisolid Systems

This technique converts a liquid medication (drug dissolved in a non-volatile, water-miscible solvent) into a free-flowing, compressible powder using porous carrier and coating materials (e.g., silica) [24]. The drug is molecularly dispersed in the liquid film covering the carrier particles. Upon contact with water, the drug is released in an already dissolved state, significantly enhancing the dissolution rate [25].

Machine Learning and Computational Approaches

Machine Learning (ML) models, trained on large datasets, are used to rapidly and accurately predict the solubility and bioavailability of new API candidates, guiding early-stage selection and structural modification [26]. Furthermore, Molecular Dynamics (MD) simulations are employed to understand drug-excipient interactions, predicting the stability of amorphous forms and optimizing the formulation ratio, thereby minimizing trial-and-error experimental work [27].




Figure 2: Enhancement of Solubility and Oral Bioavailability [26]

Comparative Analysis of Techniques

Table 1: Comparative Analysis of Techniques

Criteria	Conventional (Micronization, Salt Forms)	Advanced (ASDs, Nanosuspensions, SEDDS)	Citation
Effectiveness	Moderate, limited by crystalline properties.	High to Very High (e.g., ASDs generate supersaturation, SEDDS bypass dissolution).	[28]
Stability	Highest physical stability (crystalline state).	Physically challenged (amorphous/nanocrystalline state prone to recrystallization/aggregation).	[14, 12]
Scalability	High (mature technology).	Highly scalable (HME is continuous, SEDDS is simple mixing).	[29, 30]
Cost	Low capital and operational costs.	High capital investment (HME, HPH equipment).	[29]
Industrial Use	Very High.	High and increasing (e.g., numerous approved ASD and SEDDS products).	[30]

The enhancement technique must be rationally matched to the drug's properties (e.g., thermal stability) ^[31]. For high-energy forms (ASDs, Nanocrystals), robust stabilization (e.g., polymer selection) is the most critical factor for commercial viability ^[13]. Finally, application of Quality by Design (QbD) principles is a best practice to define and control Critical Process Parameters (CPPs) for sensitive advanced manufacturing techniques, ensuring batch-to-batch consistency and scalability ^[32, 43]. Recent studies and industrial practices have focused on the following materials and methodologies to enhance the solubility of poorly water-soluble drugs ^[39,42]

1. Amorphous Solid Dispersions (ASDs)

- **Materials:** Drug substance, hydrophilic polymers (e.g., PVP, HPMC, Soluplus)
- **Methods:** Hot-Melt Extrusion (HME): Drug and polymer are melted and extruded into a solid dispersion, *Spray Drying*: Drug-polymer solution is atomized and rapidly dried to form amorphous particles.

2. Nanosuspensions

- **Materials:** Drug, surfactants (e.g., Poloxamer 188, Tween 80), stabilizers

- **Methods:** High-Pressure Homogenization: Reduces particle size under high shear, *Media Milling*: Uses grinding media to break down drug crystals.

3. Lipid-Based Drug Delivery Systems (LBDDS)

- **Materials:** Lipids (e.g., Capryol, Labrafac), surfactants, co-solvents
- **Methods:** Self-Microemulsifying Drug Delivery Systems (SMEDDS): Formulations that spontaneously form emulsions in GI fluids.

4. Co-crystals

- **Materials:** API, co-formers (e.g., saccharin, nicotinamide)
- **Methods:** Solvent Evaporation, Grinding, or Slurry Conversion to form new crystalline structures.

5. Mesoporous Silica Carriers

- **Materials:** Mesoporous silica (e.g., MCM-41, SBA-15), drug
- **Methods:** Solvent Impregnation or Melt Adsorption to load drug into porous matrices.

Table 2: Comparative Table of Solubility Enhancement Techniques

Technique	Key Materials Used	Methodology	Advantages	Limitations
Amorphous Solid Dispersions	PVP, HPMC, Soluplus	HME, Spray Drying	High drug loading, scalable	Physical instability
Nanosuspensions	Surfactants, stabilizers	Homogenization, Milling	Enhanced dissolution, fast absorption	Agglomeration risk, complex processing
SMEDDS (LBDDS)	Lipids, surfactants, co-solvents	Self-emulsification	Improved oral bioavailability	Limited to lipophilic drugs
Co-crystals	API + co-formers	Grinding, Solvent Evaporation	Improved solubility and stability	Co-former selection critical
Mesoporous Silica Systems	MCM-41, SBA-15	Solvent loading, melt method	High surface area, controlled release	Drug leaching, scalability issues

• Regulatory and Safety Considerations

Regulatory Guidelines for Solubility Enhancement Techniques

Successful solubility enhancement can potentially lead to a Biowaiver for *in vivo* bioequivalence studies, particularly for Class II drugs that exhibit very rapid dissolution ^[33]. However, advanced systems often use novel or non-compendial excipients (e.g., new polymers, surfactants), requiring extensive regulatory

data on the excipient's safety, function, and potential toxicity [34]. Furthermore, rigorous validation of complex processes like HME and HPH is required to demonstrate control over Critical Quality Attributes (CQAs), such as amorphous content and particle size [30, 34]. The high concentrations of surfactants and co-solvents in SEDDS must be justified and safety-reviewed to prevent potential irritation or systemic toxicity [35]. The manufacturing processes must not induce chemical degradation, and the enhanced solubility should be managed to prevent localized supersaturation that could cause irritation or precipitation *in vivo* [31].

Challenges in Regulatory Approval of Novel Formulations

Providing definitive long-term stability data to guarantee no recrystallization of under stress conditions remains a key regulatory hurdle [30]. Similarly, precise and consistent control over the size and stability of nanoparticles (zeta potential, size distribution) is mandatory to ensure reproducible *in vivo* performance [20, 34]. Finally, regulatory bodies stringently require *in vitro* dissolution testing to be conducted in biorelevant media (e.g., FaSSIF/FeSSIF) to accurately predict *in vivo* behavior for advanced formulations [33].

Case Studies and Applications

Successful examples of solubility enhancement in drug development underscore the transformative potential of these techniques [28].

- **Sporanox® (Itraconazole) and Kalydenco® (Ivacaftor):** These highly lipophilic, BCS Class II drugs are commercialized as Amorphous Solid Dispersions (ASDs) [30, 39]. For Itraconazole, the ASD enables required systemic exposure regardless of gastric pH [36]. Ivacaftor's ASD ensures the low-dose drug is completely dissolved and absorbed, critical for cystic fibrosis treatment [40].
- **Emend® IV (Aprepitant) and Megace ES® (Megestrol Acetate):** These products utilize **Nanosuspension** technology. Emend IV provides a crucial intravenous route for the antiemetic Aprepitant without toxic co-solvents [20, 41].

Megace uses nanocrystals to improve dissolution, allowing for a lower, more effective liquid dose of Megestrol Acetate [42].

- **Neoral® (Cyclosporine):** This potent immunosuppressant, a difficult BCS Class II/IV drug, uses a **Self-Micro emulsifying Drug Delivery System (SMEDDS)**. The system spontaneously forms lipid droplets, delivering the drug in a pre-dissolved state, which dramatically **reduced inter-patient variability** in drug exposure [20, 35].

FUTURE PERSPECTIVES

The future of solubility enhancement will be defined by its integration with advanced computing, continuous manufacturing, and personalized medicine.

Trends in Personalized Medicine and their Impact on Solubility Enhancement

3D Printing (Additive Manufacturing), coupled with derived filaments, will enable personalized medicine by allowing for rapid, tailored dosages and precisely engineered release profiles, which can customize to individual absorption variability [37]. Furthermore, AI/ML is being developed to dynamically optimize entire formulation spaces, predicting the optimal technology and component ratios for stability and efficacy before any physical formulation begins ("rational design") [26].

Potential of Combination Therapies and Novel Drug Delivery Systems

Next-generation systems will focus on Multifunctional Nanocarriers, such as evolving Liposomes and Polymeric Micelles [18, 45]. These are being designed as targeted platforms that not only solubilize the drug but also include ligands for active targeting to specific tissues, simultaneously improving efficacy and reducing off-target toxicity [45]. Research is also exploring the use of Co-crystals as precursors in HME to control the dissolution and crystallization process in stabilized amorphous systems [15].

Research Gaps and Areas for Future Exploration



The primary scientific gap remains the accurate *in silico* prediction of drug performance in the complex GI tract, accounting for variability in bile salts, fluid volume, pH, and microbiota, which is necessary to replace static *in vitro* tests [9, 33]. Furthermore, there is a need for the development of dual-action systems that effectively address both low solubility and poor permeability for BCS Class IV drugs [7]. Finally, the industrial transition to fully continuous manufacturing (e.g., continuous HPH) requires further Process Analytical Technology to ensure real-time quality assurance [23, 43].

RESULT

Recent advancements in solubility enhancement have yielded promising outcomes across multiple formulation strategies. Key findings include:

- **Amorphous Solid Dispersions (ASDs):**
 - ASDs prepared via Hot-Melt Extrusion and Spray Drying showed significant improvement in dissolution rates for BCS Class II drugs like itraconazole and celecoxib.
 - Stability studies confirmed that polymer selection (e.g., HPMC, Soluplus) plays a critical role in maintaining amorphous state over time.
- **Nanosuspensions:**
 - Particle size reduction to sub-micron levels led to enhanced surface area and faster dissolution for drugs like fenofibrate and naproxen.
 - High-pressure homogenization produced stable nanosuspensions with consistent bioavailability.
- **Lipid-Based Drug Delivery Systems (LBDDS):**
 - SMEDDS formulations of poorly soluble APIs like ritonavir and cyclosporine demonstrated rapid emulsification and improved oral absorption.

- Lipid excipients such as Capryol and Labrafil were found to enhance solubilization capacity.

- **Co-crystals:**

- Co-crystallization with safe co-formers (e.g., nicotinamide, saccharin) improved solubility and dissolution for drugs like carbamazepine and indomethacin.

- **Mesoporous Silica Materials:**

- Drugs loaded into MCM-41 and SBA-15 showed controlled release and improved solubility due to high surface area and pore volume.

DISCUSSION

The results underscore the effectiveness of modern solubility enhancement techniques in overcoming bioavailability challenges associated with poorly water-soluble drugs. Each approach offers unique advantages:

- **ASDs** are particularly valuable for thermally stable drugs and allow scalable manufacturing, though physical instability remains a concern.
- **Nanosuspensions** provide rapid onset of action and are suitable for parenteral and oral routes, but require careful stabilization to prevent aggregation.
- **LBDDS**, especially SMEDDS, are ideal for lipophilic drugs and offer ease of oral administration, though formulation complexity and excipient compatibility must be managed.
- **Co-crystals** represent a regulatory-friendly approach with potential for intellectual property extension, but co-former selection is critical.
- **Mesoporous silica systems** offer a versatile platform for controlled release and solubility enhancement, though scalability and drug loading efficiency need further optimization.

Overall, these technologies are increasingly adopted in the pharmaceutical industry, with several

commercial products now leveraging these strategies. Continued research into hybrid systems (e.g., lipid-nano hybrids, co-crystal-ASDs) and predictive modeling for formulation design will further advance this field.

CONCLUSION:

The problem of poorly water-soluble drugs continues to challenge drug development, yet it has spurred immense innovation. Technologies like $\{\text{ASDs}\}$, Nanosuspensions, and SEDDS have provided reliable commercial solutions for numerous challenging APIs. The core insight is that overcoming poor solubility requires shifting the drug into a high-energy state (amorphous or nanocrystalline) or bypassing dissolution entirely. The critical hurdle for these advanced systems remains the long-term physical stability of the high-energy form against recrystallization or aggregation. Continued investment in Machine Learning for rational design and the mastery of continuous manufacturing techniques will ensure that a molecule's therapeutic potential is never limited by its physical properties. The future of drug development for poorly water-soluble compounds is moving toward precision pharmaceuticals, delivering safer, more effective, and patient-centric therapies.

REFERENCE

- commercial products now leveraging these strategies. Continued research into hybrid systems (e.g., lipid-nano hybrids, co-crystal-ASDs) and predictive modeling for formulation design will further advance this field.
- ## CONCLUSION:
- The problem of poorly water-soluble drugs continues to challenge drug development, yet it has spurred immense innovation. Technologies like $\text{\$}\{ASDs\}$, Nanosuspensions, and SEDDS have provided reliable commercial solutions for numerous challenging APIs. The core insight is that overcoming poor solubility requires shifting the drug into a high-energy state (amorphous or nanocrystalline) or bypassing dissolution entirely. The critical hurdle for these advanced systems remains the long-term physical stability of the high-energy form against recrystallization or aggregation. Continued investment in Machine Learning for rational design and the mastery of continuous manufacturing techniques will ensure that a molecule's therapeutic potential is never limited by its physical properties. The future of drug development for poorly water-soluble compounds is moving toward precision pharmaceuticals, delivering safer, more effective, and patient-centric therapies.
- ## REFERENCE
- Amidon, G. L., Lennernäs, H., Shah, V. P., & Crison, J. R. (1995). A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. *Pharmaceutical Research*, 12(3), 413–420.
 - Ganesh, S., Sundaran, S., & Shanker, S. R. (2021). An overview of recent advances in solubility enhancement techniques for poorly water-soluble drugs. *Journal of Drug Delivery Science and Technology*, 66, 102875.
 - Karnoub, A. E. (2017). A review on solubility enhancement techniques for poorly water-soluble drugs. *International Journal of Pharmaceutical Sciences Review and Research*, 47(1), 180–187.
 - Savjani, K. T., Gajjar, A. K., & Savjani, J. K. (2012). Drug solubility: importance and enhancement techniques. *ISRN Pharmaceutics*, 2012, 195727.
 - Di, L., & Kerns, E. H. (2008). *Drug-like properties: concepts, structure, design and methods*. John Wiley & Sons.
 - Lennernäs, H., & Abrahamsson, B. (2005). The use of Caco-2 cells in the prediction of drug absorption. In *vitro drug absorption and metabolism: A focus on Caco-2*, 107–130.
 - Shanker, K., & Varma, A. (2018). Approaches for solubility and dissolution enhancement of Class IV drugs of BCS. *Journal of Drug Delivery and Therapeutics*, 8(6-s), 237–246.
 - Noyes, A. A., & Whitney, W. R. (1897). The rate of solution of solid substances in their own solutions. *Journal of the American Chemical Society*, 19(12), 930–934.
 - Christensen, J. S., & Müllertz, A. (2021). The importance of formulation factors on the solubility and dissolution rate of poorly water-soluble drugs. *Pharmaceutics*, 13(7), 1084.
 - Müller, R. H., Jacobs, C., & Kayser, O. (2001). Nanosuspensions for the formulation of poorly soluble drugs. *European Journal of Pharmaceutics and Biopharmaceutics*, 52(1), 149–161.
 - Merisko-Liversidge, E., & Liversidge, G. G. (2011). Nanosizing for oral and parenteral drug delivery: a perspective on formulating poorly-water soluble compounds using wet media milling technology. *Advanced Drug Delivery Reviews*, 63(5-6), 427–440.
 - Bilgili, E., & Kislalioglu, M. S. (2011). A review of nanosuspensions: preparation, characterization, and applications. *Drug Development and Industrial Pharmacy*, 37(5), 629–644.
 - Curatolo, W., Johnson, S. L., & Shugarts, S. (2019). Mechanisms of solid dispersion dissolution: From a supersaturation-based platform perspective. *Journal of Controlled Release*, 311, 140–151.
 - Serajuddin, A. T. M. (2007). Salt formation to improve drug solubility and dissolution rate. *Advanced Drug Delivery Reviews*, 59(7), 603–616.
 - Douroumis, D. (2012). Co-crystals of pharmaceutical solids: recent advances and future prospects. *Expert Opinion on Drug Delivery*, 9(8), 1013–1023.
 - Yalkowsky, S. H., & Roseman, T. J. (1981). Solubilization of drugs by cosolvents.

- Physicochemical and biological drug interactions, 126–147.
17. Roy, A., & Das, S. K. (2015). Hydrotropy: A review. *International Journal of Pharmaceutical Sciences Review and Research*, 33(1), 154-159.
18. Lavasanifar, A., Samuel, J., & Kwon, G. S. (2002). Poly (ethylene oxide)–block–poly (l-amino acid) micelles for drug delivery. *Advanced Drug Delivery Reviews*, 54(2), 169–190.
19. Kesharwani, P., & Jain, N. K. (2012). Dendrimer as a promising tool for solubility enhancement. *Drug Discovery Today*, 17(17-18), 1083–1092.
20. Pouton, C. W. (2006). Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. *European Journal of Pharmaceutical Sciences*, 29(3-4), 278–287.
21. Porter, C. J. H., Trevaskis, N. L., & Charman, W. N. (2007). Lipids and lipid-based formulations: optimizing oral drug delivery. *Nature Reviews Drug Discovery*, 6(3), 231–248.
22. Reverchon, E., & De Marco, I. (2006). Supercritical fluid anti-solvent precipitation of nanoparticles of an API . *Journal of Supercritical Fluids*, 37(1), 127–134.
23. Chattopadhyay, P., & Gupta, R. B. (2002). Particle production using supercritical fluid processes. *Industrial & Engineering Chemistry Research*, 41(16), 4059–4075.
24. Spireas, S., Sadu, S., & Grover, R. (1998). In vitro and in vivo evaluation of the oral absorption of a self-emulsifying liquid compact of ibuprofen in rats. *Journal of Pharmaceutical Sciences*, 87(7), 868–874.
25. Tayel, S. A., Kassem, M. A., & Khalil, A. E. A. (2009). Enhanced dissolution of carvedilol from liquid compact tablets. *European Journal of Pharmaceutics and Biopharmaceutics*, 72(3), 633–640.
26. Dabbah, M., & Ekins, S. (2020). Machine learning approaches for solubility prediction in drug discovery: an overview and recent advances. *Computational Biology and Chemistry*, 85, 107221.
27. Llinàs, A., & Goodman, J. M. (2008). Molecular modelling of organic solids. *Molecular Informatics*, 27(5), 450–461.
28. Williams, H. D., & Trevaskis, N. L. (2018). Current applications and future directions of advanced solubility-enabling formulations. *Pharmaceutics*, 10(1), 47.
29. Balani, S. K., & Robinson, D. (2016). Challenges and opportunities in formulation of poorly water-soluble drugs. *International Journal of Pharmaceutics*, 506(1-2), 1-13.
30. Al-Hamidi, H., & Al-Amoudi, S. (2018). Amorphous solid dispersions: an enabling technology for poorly water-soluble drugs. *Pharmaceutics*, 10(4), 183.
31. Shah, K. M., & Khan, H. A. (2020). Formulation strategies for solubility enhancement of poorly water-soluble drugs. *Journal of Drug Delivery Science and Technology*, 58, 101859.
32. Junghanns, J. U. H., & Müller, R. H. (2008). Nanocrystal technology, drug delivery and clinical applications. *International Journal of Nanomedicine*, 3(3), 295–309.
33. Dressman, J. B., & Butler, J. M. (2007). Oral drug absorption: prediction and assessment. CRC Press.
34. Szabo, E., & De Marco, L. (2018). Challenges and opportunities in the regulatory landscape of complex drug products. *Journal of Pharmaceutical Sciences*, 107(12), 3020–3027.
35. Pouton, C. W., & Porter, C. J. H. (2008). Formulation of lipid-based drug delivery systems for oral administration: Materials, methods and strategies. *Advanced Drug Delivery Reviews*, 60(6), 625–631.
36. Van Speybroeck, M., & Mooter, G. V. (2011). The use of solid dispersions for the oral delivery of poorly water-soluble drugs. *European Journal of Pharmaceutical Sciences*, 43(1-2), 1-13.
37. Trenfield, S. J., & Goyanes, A. (2020). 3D printing for personalized drug development and clinical application. *Drug Discovery Today*, 25(12), 2200-2207.
38. Laitinen, R., & Rades, T. (2021). Strategies for enhancing the dissolution rate of poorly water soluble drugs. *Advanced Drug Delivery Reviews*, 174, 290-310.
39. Palanisamy, M., & Manavalan, R. (2022). Amorphous solid dispersion: A potential strategy to enhance the bioavailability of BCS Class II and IV drugs. *Journal of Drug Delivery Science and Technology*, 70, 103251.

40. Van der Velden, N. C., & Ebbens, S. J. (2020). Amorphous solid dispersions: the role of excipient properties and manufacturing process on drug release. *European Journal of Pharmaceutical Sciences*, 142, 105151.
41. Junghanns, J. U. H., & Müller, R. H. (2008). Nanocrystal technology, drug delivery and clinical applications. *International Journal of Nanomedicine*, 3(3), 295–309.
42. Sunkara, G., & Kumar, S. (2018). Nanocrystal technology: A promising approach for poorly water-soluble drugs. *Advanced Pharmaceutical Bulletin*, 8(3), 405-416.
43. Laity, P. R., & Muzzio, F. J. (2021). Continuous manufacturing of amorphous solid dispersions: Process optimization and scale-up. *International Journal of Pharmaceutics*, 601, 120530.
44. Lee, M. H., & Kim, M. G. (2023). Smart drug delivery systems: Recent advances and clinical applications. *Journal of Pharmaceutical Analysis*, 13(2), 115-128.
45. Peer, D., & Scherer, F. (2016). Nanocarriers for drug delivery to the lymphatic system. *Advanced Drug Delivery Reviews*, 97, 110-120.

HOW TO CITE: Mukta Jagtap*, Recent Trends in Solubility Enhancement Techniques for Poorly Water-Soluble Drugs, *Int. J. Sci. R. Tech.*, 2025, 2 (11), 222-231. <https://doi.org/10.5281/zenodo.17560145>